39 results about "Arteritis" patented technology

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia / reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and / or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia / reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and / or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and / or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacterium and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hemodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma, Dermatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocytopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type 1 Diabetes Mellitus, Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications, Cataracts, Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations, Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus)), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms, and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

A Chinese medicine for treating thromboangiitis obliterans, arteriosclerotic obliteration, aorto-arteritis and Raynaud's syndrome is prepared from 31 Chinese-medicinal materials including honeysuckle flower, red peony root, safflower, peach kernel, etc.

The invention relates to application of oxymatrine (oxymatrine and matrine) and glycyrrhizic acid or pharmaceutically-acceptable forms of oxymatrine and glycyrrhizic acid or derivatives of oxymatrine and glycyrrhizic, a medicine containing the compositions, also comprises matrine glycyrrhizinate and oxymatrine glycyrrhizinate, and application of the compositions to prepare medicines treating cutaneous vasculitis (allergic cutaneous vasculitis, allergic purpura, erythema elevatum diutinum, acute febrile neutrophilic dermatosis, urticarial vasculitis, pustular vasculitis, polyarteritis nodosa, pyoderma gangrenosum, eosinophilic vasculitis, eosinophilic cellulitis, pigmented purpuric dermatoses, Wegener's granulomatosis, Behcet's disease, erythema nodosum, and erythema induratum).

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia / reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and / or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

The invention belongs to the field of gene typing diagnosis, and particularly relates to a gene typing diagnosis kit for multiple granulomatous angiitis and micro-arteritis and a use method. The gene typing diagnosis kit comprises an SNP detection probe for multiple granulomatous angiitis genes and micro-arteritis genes, multiple PCR primers, multiple PCR reaction liquid, hybridization liquid and eluent. Compared with the prior art, the gene typing diagnosis kit has the following beneficial effects: by detecting the change of the expression level of specific genetic markers and disease-predisposing genes of GPA and MPA related 5 SNP sites in blood cells, the diseases are subjected to molecular genetics typing so as to distinguish GPA and MPA diseases; and the attack risk of the normal individual AAV carrying predisposing genes is evaluated, and good molecular typing efficiency is achieved.

The invention relates to a Chinese medicinal preparation for treating temporal arteritis, which is characterized by consisting of the following raw material drugs in proportion: 6 to 8g of pubescent holly root, 8 to 10g of red-rooted salvia root, 6 to 8g of raw rehmannia, 4 to 6g of suberect spatholobus stem, 6 to 8g of hemlock parsley, 4 to 6g of sea-ear shell, 4 to 6g of stiff silkworm, 6 to 9g of sophora flavescens, 8 to 10g of coix seed, 6 to 9g of Chinese angelica, 6 to 9g of red peony root, 4 to 6g of peach kernel, 3 to 6g of safflower, 4 to 6g of cattail pollen, 4 to 6g of thinleaf milkwort root-bark, and 4 to 6g of liquorice. The Chinese medicinal preparation for treating temporal arteritis has the advantages of clearing heat and cooling blood, activating blood circulation and promoting qi circulation, removing stasis and relieving pains, and takes circulation improvement as a treatment rule. Dialectical therapy is carried out clinically according to different symptoms. The Chinese medicinal preparation has the advantages of quick response, good curative effect and no toxic or side effect.

The present inventions relates generally to methods for diagnosing the presence or the risk of development or the therapy control of vasculitis, in particular, of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR) and Takayasu's arteritis in a subject, in particular, in mammals. In addition, the present invention relates to test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject. In particular, the present invention relates to a method for diagnosing the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject analyzing for the presence of antibodies against ferritin, in particular heavy chain ferritin or immunoreactive peptides thereof or ferritin analog protein, preferably bacterial ferritin analog protein, or immunoreactive peptides thereof, in a subject. The presence of antibodies against ferritin or immunoreactive peptides thereof is indicative for the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis. In particular, detection of the presence of antibodies against ferritin or immunoreactive peptides thereof, allows early diagnosis of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis.

The invention discloses the application of sophocarpine and medical salts thereof in medicines treating viral dilated cardiomyopath, viral hypertrophic cardiomyopathy, viral coronaritis, viral pericarditis, viral endocarditis, viral valvulitism, pneumonia, bronchitis, hepatitis, encephalitis, meningitis, pancreatitis, epidemic myalgia and epidemic pleurodynia which are caused by Coxsackie B virus. The sophocarpine and the medical salts thereof which are taken as medicines for treating all related internal organ diseases caused by Coxsackie B virus can increase the cure rate, reduce the death rate and cause no obvious cytotoxic effect. Meanwhile, the sophocarpine is applicable to the industrialized production due to the rich medical herb resources, simple and convenient preparation and low cost.

The invention relates to application of pharmaceutically-acceptable forms and derivatives of oxymatrines(oxymatrine, matrine and iosmatrine) to prepare medicines treating skin vasculitis (such as allergic cutaneous vasculitis, allergic purpura, erythema elevatum diutinum, acute febrile neutrophilic dermatosis, urticarial vasculitis, pustular vasculitis, polyarteritis nodosa, gnagrenous pyoderma, eosinophilic vasculitis, eosinophilic cellulitis, pigmented purpuric dermatoses, wegner granulomatosis, behcet disease, erythema nodosum, and erythema induratum).

The preparation method of injection preparation containing above 70% of arginine lipase active component with the functions of dissolving thrombosis, anticoagulant, resisting platelet agglutination and improving microcirculation for curing thrombosis, encephalatrophy, coronary heart disease, cardiac infarction, thromboangiitis obliterans, thrombotic phlebitis, Raynaud's disease, aorto-arteritis and hyperviscosity disease, etc. includes the following steps: using G75 chromatographic column to make chromatographic separation, taking Agkistrodon halys venin and dissolving it in phosphate buffer liquor, centrifugal sample-charging, column-charing, eluting with phosphate buffer liquor, collecting enzyme active peak, concentrating and freeze-drying, and using Sephadex-A25 chromatographic columnto make chromatographic separation, dissolving the chromatographic sample in Tris-HCl buffer liquor, soaking in gel with PH7.0, charging column, eluting with NaCl buffer liquor, collecting enzyme active peak, concentrating and freeze-drying to obtain dried powder.

The present invention relates to the use of piperphentonamine or pharmaceutically acceptable salts thereof to prevent / treat encephalopathy in mammals, and the use of a combination of piperphentonamine or pharmaceutically acceptable salts thereof and other medicines in manufacture a medicine to prevent / treat encephalopathy in mammals. The mammals include human beings, and the encephalopathy includes cerebral injury related diseases or cerebrovascular diseases. The cerebrovascular diseases refer to cerebral ischemia, cerebral ischemia / reperfusion-induced injury or cerebral hemorrhage. The cerebral hemorrhage includes hypertensive cerebral hemorrhage, cerebral hemorrhage secondary to infarction, tumor cerebral hemorrhage or cerebral hemorrhage caused by arteritis. The cerebral ischemia means carotid system cerebral ischemia or vertebrobasilar cerebral ischemia.

The invention relates to the technical field of data information judgment systems, in particular to a determination method based on a grading determination system for renal artery stenosis caused by aorto-arteritis. The method comprises the following steps: respectively uploading biochemical index data packets of renal artery stenosis caused by aorto-arteritis to a central cloud storage platform,a grading evaluation unit and a prognosis judgment unit; carrying out encryption storage, grading evaluation judgment and prognosis judgment respectively, and summarizing results respectively; storingthe summarized result, transmitting the result to a scheme matching unit, selecting a recommended scheme, and finally displaying a measurement result. The invention further designs a corresponding determination system which comprises a data acquisition unit, a central cloud storage platform, a grading evaluation unit, a prognosis judgment unit, a scheme matching unit and the like. By means of thesystem, assessment of renal artery stenosis caused by aorto-arteritis is standardized, long-term prognosis of a patient is improved, and the aims of effectively controlling the illness state and avoiding adverse reactions caused by excessive treatment are achieved.

Provided herein are methods for diagnosing the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like giant-cell arteritis (GCA), polymyalgia rheumatica (PMR), and Takayasu's arteritis, in a subject analyzing for the presence of antibodies against ferritin, in particular heavy chain ferritin or immunoreactive peptides thereof or ferritin analog protein, preferably bacterial ferritin analog protein, or immunoreactive peptides thereof, in a subject. In addition, test kits for use in the diagnosis of the presence or the risk of development, or for the therapy control of vasculitis, in particular of large vessel vasculitis, like GCA, PMR and Takayasu's arteritis, in a subject are also provided.

The present invention relates to methods and compositions for the treatment and diagnosis of cardiovascular disease, including, but not limited to, atherosclerosis, ischemia / reperfusion, hypertension, restenosis, and arterial inflammation. Specifically, the present invention identifies and describes genes which are differentially expressed in cardiovascular disease states, relative to their expression in normal, or non-cardiovascular disease states, and / or in response to manipulations relevant to cardiovascular disease. Further, the present invention identifies and describes genes via the ability of their gene products to interact with gene products involved in cardiovascular disease. Still further, the present invention provides methods for the identification and therapeutic use of compounds as treatments of cardiovascular disease. Moreover, the present invention provides methods for the diagnostic monitoring of patients undergoing clinical evaluation for the treatment of cardiovascular disease, and for monitoring the efficacy of compounds in clinical trials. Additionally, the present invention describes methods for the diagnostic evaluation and prognosis of various cardiovascular diseases, and for the identification of subjects exhibiting a predisposition to such conditions.

The invention discloses a traditional Chinese medicine composition for treating high blood pressure secondary to aortitis and a preparation method thereof. The composition is prepared from the following raw materials in parts by weight: ivy 10-20, and 10-20 southern snake vine , Shamrock 6‑12, Pearl Lotus 8‑15, Vitex Leaf 6‑12, Ghost Acupuncture 10‑20, Herba marmoset 6‑12, Raspberry 6‑12, Campanulaceae 8‑16. The present invention aims at the essence of the formation of immune dysfunction and internal invasion of rheumatism, one is based on the method of dispelling wind and promoting dampness, and applying ivy, sagera and samanthus to dispel wind and dampness medicines to dispel evil spirits, enhance body immunity, and Seeking to achieve the purpose of strengthening the body and eliminating pathogenic factors; the second is based on the fact that wind diseases can dissipate blood stasis and become poisonous for a long time. The blood circulation is not smooth, and the application of detoxification and phlegm-resolving drugs can achieve the effects of reducing phlegm and reducing turbidity, eliminating blood stasis and detoxifying by eliminating pathological products.

The invention discloses a drug for treating aorto-arteritis. The drug for treating the aorto-arteritis is prepared by the following raw materials according to a weight gram number: 80-120 g of American ginseng, 100-200 g of astragalus membranaceus, 50-150 g of fructus aurantii, 160-200 g of cinnamomum cassia presl, 60-100 g of western tangkuei, 50-70 g of ligusticum wallichii, 100-200 g of herba epimedii, 80-120 g of fried eucommia ulmoides, 60-100 g of radix aristolochiae, 50-70 g of rhizoma corydalis, 80-120 g of vinegar processing radix bupleuri, and 50-70 g of curcuma sichuaensis. The Chinese herbal medicine compound preparation is capable of emphasizing monarch, minster, assistant and guide so as to develop the synergistic effect, and treating both symptoms and root causes, has the ideal effect of enhancing resistance and inhibiting an inflammatory reaction, and is capable of overcoming and avoiding the western medicine side effect so as to achieve an expected purpose of long-termaction, wherein the drug efficacy is more stable and lasting, and the drug has clinical application value and curative effect.

The invention discloses a construction method of an anterior ischemic optic neuropathy pigment rabbit model, and belongs to the field of ophthalmic disease animal models. The method comprises the following steps of adding 10%+ / -3% by weight of lard and 1%+ / -0.5% by weight of cholesterol into rabbit maintenance feed, and continuously feeding pigment rabbits for more than 24 weeks. The method provided by the invention can enable the animals to generate symptoms of non-arterial inflammatory anterior ischemic optic neuropathy only by diet control, is simple and convenient, and is easy for industrial application.

The invention discloses an external prescription for controlling temporal arteritis and a preparation method thereof. Raw materials of the external prescription are prepared from the following components in percentage by mass: 10%-35% of galium verum, 2%-25% of coptis chinensis, 2%-25% of cuscuta japonica, 2%-30% of concha haliotidis, 0.1%-10% of bear gall, 2%-25% of pseudo-ginseng, 2%-20% of safflower, 2%-30% of pubescent holly root, 0.1%-5% of pentadecanone and 0.1%-5% of borneol. The preparation method mainly comprises the step of dipping through alcohol. The external prescription is convenient to use, has a very good effect on various types of eye inflammations, can completely control the eye inflammations and reverse visual impairment aiming at temporal arteritis eye diseases, and canrealize reseeing of blinded eyes to be bright.

There is provided the use of a functional thylakoid extract, particularly in admixture with a physiologically acceptable carrier, in pharmaceutical application, in the treatment of cardiovascular diseases, and method for the treatment thereof. The cardiovascular diseases (CVD) may comprise several diseases associated with inflammation of the heart or arteries and include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack), atherosclerosis, stroke, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, and venous thrombosis.

The invention discloses traditional Chinese medicine for treating thoraco-abdominal aorta type multiple aorto-arteritis. The traditional Chinese medicine is characterized by being prepared by mixing the following raw materials in parts by weight: 5 parts of dried rehmannia root, 20 parts of semen brassicae, 20 parts of deer-horn glue, 10 parts of charred ginger, 10 parts of cassia, 5 parts of rhizophora mucronata, 5 parts of Chinese angelica, 10 parts of honeysuckle, 20 parts of dendrobium nobile, 20 parts of peach seed, 30 parts of safflower, 20 parts of endothelium corneum gigeriae galli, 10 parts of earthworm, 25 parts of achyranthes bidentata, and 25 parts of codonopsis pilosula. The traditional Chinese medicine provided by the invention adopts proper herbs and a proper ratio for mutual cooperation among different medications, has a synergy effect, has the function of promoting blood circulation to remove meridian obstruction, and relieving pain, and can effectively treat thoraco-abdominal aorta type multiple aorto-arteritis; use result of 30 patients of thoraco-abdominal aorta type multiple aorto-arteritis over 6 years shows that the traditional Chinese medicine has an effective percentage over 83.3%.

The invention discloses the application of 25-hydroxyvitamin D in preparing a kit for judging and / or assisting judging disease activity of patients with Takayasu arteritis. The invention also discloses a kit for judging and / or assisting judging disease activity of patients with Takayasu arteritis, which includes products for detecting the content of 25-hydroxyvitamin D in biological samples of Takayasu patients; the kit also includes A carrier that records the following judgment criteria: when the concentration of 25-hydroxyvitamin D in the biological sample is lower than 15.98ng / ml, it is determined that the patient is in the active stage of Takayasu arteritis; when the concentration of 25-hydroxyvitamin D in the biological sample If the concentration of D is equal to or higher than 15.98ng / ml, it is determined that the patient is in the latent stage of Takayasu arteritis.